Login to Your Account

ITP Space Growing

MGI Paying $45M Up Front For Thrombocytopenia Drug

By Jennifer Boggs

Thursday, August 30, 2007
With a new drug application for its sedative product, Aquavan, nearing submission, MGI Pharma Inc. decided to add a new drug to its development pipeline, gaining rights to a midstage thrombocytopenia drug from small biotech firm AkaRx Inc. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription